Pfizer said on Thursday it will stop global development and commercialization of its hemophilia gene therapy, Beqvez, citing ...

Pfizer (NYSE:PFE) has decided to end R&D and marketing activities related to Beqvez, a one-time gene therapy the company has ...

Pfizer (PFE) will end global development and commercialization of Beqvez, a gene therapy for hemophilia, Nikkei learned Thursday, after the ...

NEW YORK/TOKYO -- Pfizer will end global development and commercialization of Beqvez, a gene therapy for hemophilia, Nikkei learned Thursday, after the drugmaker dropped its other similar treatment ...

Pfizer will end global development of its bleeding disorder gene therapy, Beqvez, the Nikkei reported on Thursday.

An intriguing battle is brewing in the market to treat patients with transthyretin amyloid cardiomyopathy (ATTR-CM). | BridgeBio reported that 1,028 unique prescriptions have been written by 516 ...

Ionis relies on upfront payments and licensing fees from partners, as well as Spinraza royalties, to drive revenue today, but its rapidly advancing portfolio should help diversify revenue. 2025 is ...

It is the first time that a significant stake in Firmdale has been sold to an external investor since it was founded in 1985 ...

Trump previously met with Ubl and chief executives of U.S. drugmakers Pfizer and Eli Lilly at his Mar-a-Lago estate in Florida in December.

U.S. President Donald Trump is set to meet with top pharmaceutical executives on Thursday, a White House official confirmed. The discussions will focus on Medicare drug price negotiations, pharmacy ...

U.S. President Donald Trump will meet on Thursday with chief executives from major drugmakers, a White House official ...

Nanoparticle characterization is vital for mRNA vaccine efficacy, ensuring safety and regulatory compliance in the ...